161 related articles for article (PubMed ID: 12709332)
1. Pharmacodynamics of a novel des-F(6)-quinolone, BMS-284756, against Streptococcus pneumoniae in the thigh infection model.
Nicolau DP; Mattoes HM; Banevicius M; Xuan D; Nightingale CH
Antimicrob Agents Chemother; 2003 May; 47(5):1630-5. PubMed ID: 12709332
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model.
Andes D; Craig WA
Antimicrob Agents Chemother; 2003 Dec; 47(12):3935-41. PubMed ID: 14638504
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae.
Mattoes HM; Banevicius M; Li D; Turley C; Xuan D; Nightingale CH; Nicolau DP
Antimicrob Agents Chemother; 2001 Jul; 45(7):2092-7. PubMed ID: 11408228
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models.
Andes D; Craig WA
Antimicrob Agents Chemother; 2002 Jun; 46(6):1665-70. PubMed ID: 12019073
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model.
Tessier PR; Mattoes HM; Dandekar PK; Nightingale CH; Nicolau DP
Antimicrob Agents Chemother; 2005 Jan; 49(1):188-94. PubMed ID: 15616295
[TBL] [Abstract][Full Text] [Related]
6. In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus.
Lepak AJ; Seiler P; Surivet JP; Ritz D; Kohl C; Andes DR
Antimicrob Agents Chemother; 2016 Jun; 60(6):3626-32. PubMed ID: 27044547
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model.
Xuan D; Banevicius M; Capitano B; Kim MK; Nightingale C; Nicolau D
Antimicrob Agents Chemother; 2002 Sep; 46(9):2990-5. PubMed ID: 12183258
[TBL] [Abstract][Full Text] [Related]
8. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
Andes D; Craig WA
Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
[TBL] [Abstract][Full Text] [Related]
9. In vivo pharmacodynamics of a new oxazolidinone (linezolid).
Andes D; van Ogtrop ML; Peng J; Craig WA
Antimicrob Agents Chemother; 2002 Nov; 46(11):3484-9. PubMed ID: 12384354
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
Bulik CC; Okusanya ÓO; Lakota EA; Forrest A; Bhavnani SM; Hoover JL; Andes DR; Ambrose PG
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872075
[TBL] [Abstract][Full Text] [Related]
11. Determination of the pharmacodynamic profile of daptomycin against Streptococcus pneumoniae isolates with varying susceptibility to penicillin in a murine thigh infection model.
Dandekar PK; Tessier PR; Williams P; Zhang C; Nightingale CH; Nicolau DP
Chemotherapy; 2004 Apr; 50(1):11-6. PubMed ID: 15084799
[TBL] [Abstract][Full Text] [Related]
12. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model.
MacGowan AP; Rogers CA; Holt HA; Bowker KE
Antimicrob Agents Chemother; 2003 Mar; 47(3):1088-95. PubMed ID: 12604546
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection models.
Andes D; Craig WA
Antimicrob Agents Chemother; 2006 Jan; 50(1):243-9. PubMed ID: 16377693
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics to combat resistance.
Woodnutt G
J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():25-31. PubMed ID: 10997596
[TBL] [Abstract][Full Text] [Related]
15. Impact of AUC/MIC ratios on the pharmacodynamics of the des-F(6) quinolone garenoxacin (BMS-284756) is similar to other fluoroquinolones.
Lister PD
J Antimicrob Chemother; 2003 Jan; 51(1):199-202. PubMed ID: 12493819
[No Abstract] [Full Text] [Related]
16. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.
Andes D; Craig WA
Antimicrob Agents Chemother; 2006 Apr; 50(4):1376-83. PubMed ID: 16569855
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of survival and pharmacodynamic relationships for five fluoroquinolones in a neutropenic murine model of pneumococcal lung infection.
Ernst EJ; Klepser ME; Petzold CR; Doern GV
Pharmacotherapy; 2002 Apr; 22(4):463-70. PubMed ID: 11939681
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios.
Scaglione F; Mouton JW; Mattina R; Fraschini F
Antimicrob Agents Chemother; 2003 Sep; 47(9):2749-55. PubMed ID: 12936969
[TBL] [Abstract][Full Text] [Related]
19. In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model.
Fukuda Y; Yanagihara K; Ohno H; Higashiyama Y; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Mizuta Y; Tashiro T; Kohno S
Antimicrob Agents Chemother; 2006 Jan; 50(1):121-5. PubMed ID: 16377676
[TBL] [Abstract][Full Text] [Related]
20. AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.
Zelenitsky SA; Ariano RE; Iacovides H; Sun S; Harding GK
J Antimicrob Chemother; 2003 Apr; 51(4):905-11. PubMed ID: 12654762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
